In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly sells manufacturing site to Covance, signs R&D contract

Executive Summary

Eli Lilly announced that it has sold to CRO Covance its 450-acre preclinical drug development facility in Greenfield, Indiana for $50mm up front. The companies have also entered into an agreement where Covance will provide Lilly with various drug development services over the next ten years, a partnership valued at about $1.6bn.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies